Medication-related Osteonecrosis of the Jaw (MRONJ) Registry

Approximately 500 patients diagnosed with medication-related osteonecrosis of the jaw will be
enrolled in the study. Patients will undergo standard (routine) of care treatment, either
conservative or surgical or both, and followed up during one year after the initiation of the
treatment. Treatment outcome (development of the condition), pain and complications will be
collected and documented over the duration of the registry.

Inclusion Criteria:

- Age > 18 years

- Newly diagnosed patients with osteonecrosis in a facial bone other than the jaw, or

- Newly diagnosed patients with non-exposed MRONJ (stage 0), or

- Newly diagnosed patients with exposed MRONJ, i.e:

- Current or previous treatment with antiresorptive or antiangiogenic agents.

- Exposed bone or bone that can be probed through an intraoral or extraoral
fistula(e) in the maxillofacial region that has persisted for more than 8 weeks

- No history of radiation therapy to the jaws or obvious metastatic diseases of the
jaw

- Ability to understand the content of the patient information/ Informed Consent Form

- Willingness and ability to participate in the clinical investigation according to the
Registry Plan (RP)

- Signed and dated IRB/EC-approved written informed consent

- Mental capacity to comply with post-operative regimen, evaluation and data collection

Exclusion Criteria:

- Recent history of substance abuse (i. e., recreational drugs, alcohol) that would
preclude reliable assessment

- Pregnancy or women planning to conceive within the registry period

- Prisoner

- Participation in any other medical device or medicinal product study within the
previous month that could influence the results of the present registry